Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
Merck
Boehringer Ingelheim
Deloitte
Citi
Johnson and Johnson
Cantor Fitzgerald
Chubb

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,871,759

« Back to Dashboard

Which drugs does patent 8,871,759 protect, and when does it expire?

Patent 8,871,759 protects ZEPATIER and is included in one NDA.

This patent has forty-one patent family members in thirty-three countries.
Summary for Patent: 8,871,759
Title:Inhibitors of hepatitis C virus replication
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. ##STR00001##
Inventor(s): Coburn; Craig A. (Royersford, PA), Ludmerer; Steven W. (North Wales, PA), Liu; Kun (Edison, NJ), Wu; Hao (Shanghai, CN), Soll; Richard (San Diego, CA), Zhong; Bin (Shanghai, CN), Zhu; Jian (Shanghai, CN)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/260,684
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,871,759

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,871,759

PCT Information
PCT FiledMarch 25, 2010PCT Application Number:PCT/US2010/028653
PCT Publication Date:September 30, 2010PCT Publication Number: WO2010/111483

Non-Orange Book US Patents Family Members for Patent 8,871,759

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,090,661 Inhibitors of hepatitis C virus replication ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Teva
Argus Health
Colorcon
AstraZeneca
US Department of Justice
Fuji
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.